Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863472 | 0.98 | L3MBTL1 (0.60) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL2719923 | 0.92 | KDM1A (0.54) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL18663232 | 0.85 | KDM1A (0.59) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL4202090 | 0.82 | CHRM2 (0.50) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL19540778 | 0.79 | KDM1A (0.53) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL2094368 | 0.78 | KDM1A (0.46) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL18677977 | 0.78 | KDM1A (0.52) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL6896740 | 0.78 | SLC6A2 (0.50) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL18677909 | 0.78 | KDM1A (0.52) | L3MBTL1HPGDKDM1AKMT2APOLB | |
| SCHEMBL18674516 | 0.78 | KDM1A (0.52) | L3MBTL1HPGDKDM1AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-7776879-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2010-08-17 | — | — | US | disclosed |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | disclosed |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG | 2008-01-24 | — | — | US | disclosed |
| CN-100363363-C | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL PRODESFARMA SA (CH) | 2008-01-23 | — | — | CN | disclosed |
| US-7312231-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-12-25 | — | — | US | disclosed |
| US-7208501-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-04-24 | — | — | US | disclosed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
| EP-1345937-B1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-09-28 | — | — | EP | disclosed |
| CN-1675206-A | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL PRODESFARMA SA (CH) | 2005-09-28 | — | — | CN | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2004-12-30 | — | — | US | disclosed |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | LABORATORIOS ALMIRALL S.A. (ES) | 2004-12-02 | — | — | US | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| EP-1345937-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051841-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | L3MBTL1 4595/4885HPGD 2312/4885KDM1A 1064/4885 |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | CHRM3, CHRM2, CHRM1 | L3MBTL1 4702/4885HPGD 2118/4885KDM1A 1086/4885 |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | L3MBTL1 1291/4885HPGD 1286/4885KDM1A 2318/4885 |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | L3MBTL1 2683/4885HPGD 4155/4885KDM1A 528/4885 |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | L3MBTL1 2808/4885HPGD 4085/4885KDM1A 517/4885 |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM1, CHRM2 | L3MBTL1 2461/4885HPGD 4127/4885KDM1A 401/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | L3MBTL1 4397/4885HPGD 2262/4885KDM1A 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.